OUTBRAIN
16.1.2019 12:02:11 CET | Business Wire | Press release
Outbrain , the world’s leading native advertising platform, announced today it has signed a pan-regional deal with Eurosport, the number one destination for sports fans. The agreement spans 13 markets globally, including the UK, France, Germany, Italy, Spain, Asia, and Australia, and will be powered by Outbrain’s innovative Smartfeed technology.
Smartfeed provides a content discovery feed that allows publishers to customise the user experience, improving both engagement and revenue. It is designed for a range of content from promoted articles to editorial pieces to videos, and functions across all devices including desktop, mobile, and apps.
Eurosport will also utilise Outbrain’s Amplify platform to promote their own videos. Earlier this year, Outbrain released Focus, a click-to-watch video experience built for engagement and performance, and tailored for high quality and long form video content. Focus consistently results in higher click-through and completion rates, which makes it ideally suited to grow Eurosport’s following on its own video platform, the Eurosport Player.
“We are very excited about this partnership with Eurosport. Our aim at Outbrain is to provide smart and flexible technology that drives personalised content recommendations while optimising revenue. Smartfeed has already resulted in a 60% average increase in organic CTR and a 40% average increase in publisher revenue. Our deal with Eurosport also includes Native video, which makes Smartfeed even more effective. We look forward to building a strong partnership together.” said Stephanie Himoff, Managing Director of Northern Europe.
“Outbrain’s Smartfeed and Amplify technology is great for us.” said David Fisher, VP of Digital Ads at Eurosport. “We want to leverage Outbrain’s platforms to grow our fan base and surface our own video content in a prominent manner, as well as driving significant monetisation. We are really looking forward to working with Outbrain.”
In addition, this partnership with Eurosport furthers Outbrain’s reach by tapping into key audiences globally. Eurosport has locally managed sports sites in France, Italy, Spain, UK, Germany, and Russia; and Eurosport.com alone sees 42 million visitors monthly to its site.
About Outbrain
Founded in 2006, Outbrain's mission is to create the most meaningful and trustworthy online discovery feeds connecting a person, channel and marketer. Outbrain’s native advertising technology powers the news, product & information feeds of the world’s most recognized publishers and channels including MSN, CNN, BBC, The Washington Post, The Guardian, and Sky News. Outbrain is headquartered in New York with offices in 15 cities worldwide. Learn more at outbrain.com or follow us on Twitter , LinkedIn or Instagram .
About Eurosport
Eurosport is the number one sport destination in Europe, fuelling the passion of fans and connecting them with the greatest sports events in the world. As the Home of the Olympic Games in Europe, Eurosport delivered the ultimate Games experience for PyeongChang 2018 reaching both record linear and digital viewership across localized Eurosport services. Firmly established as the Home of Cycling, Grand Slam Tennis and Winter Sport, Eurosport channels – Eurosport 1, Eurosport 2 – reach 242 million cumulative subscribers across 75 countries in Europe, Asia Pacific, Africa and the Middle East. Eurosport.com is Europe’s No 1 online sports news website with an average of 42 million unique users per month and, along with the Eurosport app (available on iOS and Android), the only place to watch Eurosport anytime online, on mobile and on tablet devices. Eurosport Events specializes in the management and promotion of international sporting events. More information is available by visiting corporate.eurosport.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190116005100/en/
Contact:
For all press enquiries please contact : Karen Walden Marketing & PR, Northern Europe at Outbrain kwalden@outbrain.com Eurosport Steve Stammers Senior Communications Manager, Eurosport E: steve_stammers@discovery.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom